Windtree Therapeutics, BNB Token Treasury Firm, Faces NASDAQ Delisting

Healthcare company Windtree Therapeutics, known for its work on respiratory disease, is set to be delisted from the NASDAQ stock market index due to noncompliance with its regulations. The company, which recently adopted the BNB coin as part of its strategic reserve, failed to maintain a minimum share price of $1.00, leading to its removal from the index.

Despite an initial investment of $60 million and an expected additional $140 million from Build And Build Corp., the company's stock has seen a drastic drop. Meanwhile, the BNB asset the company invested in has performed well, raising questions about the company's strategy. Other treasury companies like Strategy have also seen a drop in their stock, suggesting a possible industry-wide issue.